Nicholas Kipshidze

Dr. Nicholas Kipshidze


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Nature Photonics
Verified
Journal Article
Open access
PDF file
NKNicholas Kipshidze
Nicholas Kipshidze
NYNicholas Yeo
Nicholas Yeo
NKNodar Kipshidze
Nodar Kipshidze

1 January 2016 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ZKZurab Kakabadze
Zurab Kakabadze
NKNicholas Kipshidze
Nicholas Kipshidze
KMKonstantine Mardaleishvili
Konstantine Mardaleishvili
GCGocha Chutkerashvili
Gocha Chutkerashvili
ICIrakli Chelishvili
Irakli Chelishvili
KCKonstantine Chutkerashvili
Konstantine Chutkerashvili
Introduction. A total of 18 patients, with complete motor deficits and paraplegia caused by thoracic and lumbar spine trauma without muscle atrophy or psychiatric problems, were included into this study. Materials and Methods. The bone marrow was aspirated from the anterior iliac crest under local anesthesia and the mononuclear fraction was isolated by density gradient method. At least 750 million mononuclear‐enriched cells, suspended in 2 mL of saline, were infused intrathecally. Results and Discussion. The study reports demonstrated improvement of motor and sensory functions of various degrees observed in 9 of the 18 (50%) cases after bone marrow stem cell transplantation. Measured by the American Spinal Injury Association (ASIA) scale, 7 (78%) out of the 9 patients observed an improvement by one grade, while two cases (22%) saw an improvement by two grades. However, there were no cases in which the condition was improved by three grades. Conclusions. Analysis of subsequent treatment results indicated that the transplantation of mononuclear‐enriched autologous BMSCs is a feasible and safe technique. However, successful application of the BMSCs in the clinical practice is associated with the necessity of executing more detailed examinations to evaluate the effect of BMSCs on the patients with spinal cord injury.

8 April 2021 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
NKNicholas Kipshidze
Nicholas Kipshidze
NKNodar Kipshidze
Nodar Kipshidze
MFMartin Fried
Martin Fried

1 September 2020 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
NKNicholas Kipshidze
Nicholas Kipshidze
NYNicholas Yeo
Nicholas Yeo
NKNodar Kipshidze
Nodar Kipshidze

22 June 2022 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ZKZurab Kakabadze
Zurab Kakabadze
NKNicholas Kipshidze
Nicholas Kipshidze
TPTeona Paresishvili
Teona Paresishvili
NKNodar Kipshidze
Nodar Kipshidze
ZVZurab Vadachkoria
Zurab Vadachkoria
DCDavid Chakhunashvili
David Chakhunashvili
The acute respiratory distress syndrome (ARDS) is one of the main causes of high mortality in patients with coronavirus (COVID-19). In recent years, due to the coronavirus pandemic, the number of patients with ARDS has increased significantly. Unfortunately, until now, there are no effective treatments for ARDS caused by COVID-19. Many drugs are either ineffective or have a low effect. Currently, there have been reports of efficient use of mesenchymal stem cells (MSCs) for the treatment of ARDS caused by COVID-19. We investigated the influence of freeze-dried human placenta-derived mesenchymal stem cells (HPMSCs) in ARDS rat model. All animals have received intratracheal injection of 6mg/kg of lipopolysaccharide (LPS). The rats were randomly divided into five groups: I: LPS, II: LPS+dexamethasone, III: LPS+HPMSCs, IV: HPMSC, and V: saline. ARDS observation time was short-term and amounted to 168 hours. The study has shown that HPMSCs are able to migrate and attach to damaged lung tissue, contributing to the resolution of pathology, restoration of function, and tissue repair in the alveolar space. Studies have also shown that the administration of HPMSCs in animals with ARDS model significantly reduced the levels of key cytokines such as IL-1β, IL-6, and TNF-α. Freeze-dried placental stem cell is a very promising biomaterial for the treatment of ARDS. The human placenta can be easily obtained because it is considered as a medical waste. At the same time, a huge number of MSCs can be obtained from the placental tissue, and there is no ethical controversy around their use. The freeze-dried MSCs from human placental tissue can be stored sterile at room temperature for a long time before use.

1 October 2020 in Medical Hypotheses
Verified
Journal Article
Closed access
NKNicholas Kipshidze
Nicholas Kipshidze
VCValeri S. Chekanov
Valeri S. Chekanov
NKNodar Kipshidze
Nodar Kipshidze
VRVivek Y. Reddy
Vivek Y. Reddy
GDGeorge Dangas
George Dangas